Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18799858 | 0.95 | LMNA (0.40) | KCNH2LMNAKDM4ECYP3A4TSHR | |
| SCHEMBL28870870 | 0.88 | KCNH2 (0.41) | KCNH2LMNAKDM4ECYP3A4TSHR | |
| SCHEMBL13533992 | 0.87 | KDM4E (0.50) | LMNAKDM4ECYP3A4TSHRL3MBTL1 | |
| SCHEMBL27345654 | 0.82 | KCNH2 (0.42) | KCNH2LMNAKDM4ECYP3A4TSHR | |
| SCHEMBL11994370 | 0.80 | CYP1A2 (0.46) | LMNAKDM4ECYP3A4TSHRSREBF2 | |
| SCHEMBL6638892 | 0.79 | KDM4E (0.38) | LMNAKDM4ECYP3A4TSHRCYP1A2 | |
| SCHEMBL20280911 | 0.79 | HRH1 (0.46) | LMNAKDM4ECYP3A4TSHRTDP1 | |
| SCHEMBL12394763 | 0.79 | HRH4 (0.40) | LMNAKDM4ECYP3A4TSHRLNPEP | |
| SCHEMBL1328611 | 0.78 | LNPEP (0.48) | KCNH2LMNAKDM4ECYP3A4TSHR | |
| SCHEMBL2553622 | 0.77 | CYP3A4 (0.46) | KCNH2LMNAKDM4ECYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| CN-102802600-B | As 2,4-disubstituted pyridines of perfuming component | FIRMENICH S.A. (CH) | 2016-04-13 | — | — | CN | disclosed |
| US-8652452-B2 | 2,4-disubstituted pyridines as perfuming ingredients | FIRMENICH SA (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2552395-B1 | 2,4-disubstituted pyridines as perfuming ingredients | FIRMENICH & CIE (CH) | 2013-11-13 | — | — | EP | disclosed |
| EP-2552395-A1 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS | Firmenich S.A. (CH) | 2013-02-06 | — | — | EP | disclosed |
| US-20130004447-A1 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2013-01-03 | — | — | US | disclosed |
| WO-2011121469-A1 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004447-A1 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS | P2RX5, P2RX4, C5 | KCNH2 184/4885LMNA 3310/4885KDM4E 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.